Migraine and Triptans

From a Western clinical perspective, migraine is a neurovascular disorder characterized by cortical hyperexcitability and activation of the trigeminovascular system. This activation releases vasoactive neuropeptides—particularly CGRP—leading to sterile neurogenic inflammation and sensitization of pain pathways. Triptans directly target this cascade as selective agonists at serotonin 5‑HT1B/1D (and variably 1F) receptors on trigeminal terminals and cranial vessels. By curbing CGRP release, inhibiting nociceptive transmission in the trigeminal nucleus caudalis, and reversing pathologic cranial vasodilation, they shorten attacks and alleviate photophobia, phonophobia, and nausea. Robust randomized trials and meta‑analyses show that all marketed triptans outperform placebo for short‑term relief; however, their profiles differ. Subcutaneous sumatriptan delivers the fastest onset and highest early response, making it well‑suited to explosive attacks or those with vomiting. Oral rizatriptan and eletriptan often rank highly for two‑hour pain freedom, while longer‑acting naratriptan and frovatriptan may reduce recurrence at the cost of slower onset. Non‑oral nasal sprays and powders help when gastric stasis impairs absorption. Clinical strategy prioritizes treating early, matching formulation to the attack, and considering combination therapy. Co‑administration with naproxen enhances efficacy and durability, and antiemetics improve both symptoms and pharmacokinetics. Safety remains paramount. Because 5‑HT1B activation can constrict coronary and other arteries, triptans are contraindicated in ischemic heart disease, cerebrovascular disease, peripheral vascular disease, and uncontrolled hypertension, and are not labeled for hemiplegic or migraine with brainstem aura. They should not be combined within 24 hours with ergot derivatives or another triptan. Interactions include increased rizatriptan exposure with propranolol, CYP3A4 inhibition concerns for eletriptan, and MAO‑A interactions for several triptans. Although warnings about serotonin syndrome with SSRIs/SNRIs persist, large observational data suggest very low absolute risk; counseling and monitoring are appropriate. In pregnancy and lactation, sumatriptan holds the most reassuring (though not definitive) data; shared decision‑making is standard. When triptans are ineffective, poorly tolerated, overused, or contraindicated, alternatives include ditans (lasmiditan) and gepants (ubrogepant, rimegepant, zavegepant) that act without vasoconstriction. Preventive therapies—CGRP monoclonal antibodies, topiramate, beta‑blockers, onabotulinumtoxinA—reduce attack frequency and limit medication‑overuse headache, a recognized risk when triptans are used on ≥10 days per month for several months.

Traditional and integrative perspectives understand migraine as a manifestation of system‑level imbalance. In Traditional Chinese Medicine (TCM), patterns such as Liver yang rising, internal Wind, Phlegm‑Damp obstruction, or Blood stasis can direct pain to the head, often triggered by stress, menstrual shifts, or diet. Treatment seeks to course Liver Qi, subdue yang, dispel Wind, and open collaterals, using acupuncture, moxibustion, and individualized herbal formulas. From an Ayurvedic lens, migraines often reflect aggravated Vata (irregularity, pain) and Pitta (heat, inflammation), so care emphasizes pacifying these doshas through diet (cooling, regular meals), daily routines, oil therapies (abhyanga, shirodhara), and targeted botanicals under practitioner guidance. While these frameworks differ from receptor‑based pharmacology, integrative care often aligns with neurologic goals: reduce attack frequency, blunt triggers, and decrease central sensitization. Acupuncture has moderate‑quality evidence for prophylaxis, with some data suggesting benefit for acute pain as well, and it may reduce reliance on acute medicines like triptans. Mind–body practices—yoga, meditation, breathing techniques—address autonomic imbalance and stress reactivity, common precipitants of attacks. Nutrient approaches such as magnesium and riboflavin have supportive, though variable, clinical evidence and are widely used in integrative neurology. Herbal medicines require careful safety consideration. Classic TCM formulas (e.g., those containing Chuanxiong) are chosen by pattern and adjusted to the individual; quality control and herb–drug interaction checks are essential. Western botanicals like feverfew show mixed results, and butterbur should only be considered if certified pyrrolizidine‑alkaloid–free due to hepatotoxicity concerns and under professional supervision. In practice, triptans can coexist with these modalities: triptans provide focused relief during an attack, while acupuncture, lifestyle regulation, and selected supplements may reduce attack frequency and medication‑overuse risk. Collaborative care—clear diagnosis, trigger management, prevention strategies, and judicious acute therapy—respects both traditions and centers patient safety.